Aerie Pharmaceuticals Inc. (AERI)
Symbol Info
Listed Symbol AERI
Name Aerie Pharmaceuticals Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $24,181,000
Latest Fiscal EPS $-5.52
Price Info
21 Day Moving Average $20.2733
21 Day EMA $20.333820
50 Day Moving Average $21.5148
50 Day EMA $21.754590
200 Day EMA $32.045220
200 Day Moving Average 33.948550
52 Week High $60.05
52 Week Low $17.51
52 Week Change $-64.789700
Alpha 0.018356
Beta 0.4763
Standard Deviation 0.222906
R2 0.005384
Periods 60
Share Information
10 Day Average Volume 1,858,829
20 Day Average Volume 1,465,872
30 Day Average Volume 1,486,180
50 Day Average Volume 1,334,099
Outstanding Shares 45,939,243
Float Shares 45,119,485
Percent Float 98.22%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 418
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 6,781,866
Institute Holdings Percent -
Institute Sold Previous 3 Months 5,001,938
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 2
Insider Holdings Percent 1.80%
Insider Sold Previous 3 Months -
Insiders Shares Owned 819,758
Price Change
7 Day Price Change $0.3600006
7 Day Percent Change 1.79%
21 Day Price Change $0.1700001
21 Day Percent Change 0.84%
30 Day Price Change $-1.1299992
30 Day Percent Change -5.22%
Month To Date Price Change $1.2900
Month To Date Percent 6.71%
90 Day Price Change $-3.110001
90 Day Percent Change -13.17%
Quarter To Date $1.290001
Quarter To Date Percent 6.71%
180 Day Price Change $-18.659998
180 Day Percent Change -47.64%
200 Day Price Change $-26.97
200 Day Percent Change -56.80%
Year To Date $-15.589998
Year To Date Percent -43.19%
Profile
Description Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. Its main products are Rhopressa and Roclatan. The company mainly operates in North America.
Details
Issue Type CS
Market Cap $942,213,874
Sec Type EQS
Auditor PricewaterhouseCoopers LLP
Total Shares Outstanding 45,939,243
CEO Vicente Anido
Employees 353
Last Audit UQ
Classification
CIK 0001337553
Industry Drug Manufacturers
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 4301 Emperor Boulevard
Suite 400
Durham, NC 27703
Website http://www.aeriepharma.com
Facisimile
Telephone +1 919 237-5300
Email rrubino@aeriepharma.com
Key Ratios
Profitability
EBIT Margin -470.9
EBITDA Margin -453.8
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin 96.60
Profit Margin TOT -
Income Statements
Revenue $41,143,000
Revenue Per Share $0.8956
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $792,321,250
Price To Sales 22.900953
Price To Free Cash -7.1
PE High Last 5 Years -
Price To Book 5.7
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 5.7
Financial Strength
Total Debt To Equity 0.1
Int Coverage -58.2
Current Ratio 2.5
Leverage Ratio 1.5
Quick Ratio 2.2
Long Term Debt To Capital 0.08
Assets
Receivables Turnover 2.9
Invoice Turnover 0.20
Assets Turnover 0.10
Management Effectiveness
Return Assets -79.02
Return On Equity -132.31
Return On Capital -92.66
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
AERI
Aerie Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.